Genomic Health (GHDX) Releases FY19 Earnings Guidance

Genomic Health (NASDAQ:GHDX) updated its FY19 earnings guidance on Wednesday. The company provided earnings per share guidance of $1.38-1.54 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.25. The company issued revenue guidance of $436-448 million, compared to the consensus revenue estimate of $439.74 million.

GHDX has been the subject of a number of recent research reports. Needham & Company LLC increased their target price on Genomic Health from $86.00 to $97.00 and gave the stock a strong-buy rating in a report on Thursday. Piper Jaffray Companies raised their price objective on Genomic Health to $86.00 and gave the stock a neutral rating in a research note on Thursday. ValuEngine cut Genomic Health from a strong-buy rating to a buy rating in a report on Tuesday, December 11th. Canaccord Genuity reiterated a buy rating and set a $82.00 price target (up previously from $70.00) on shares of Genomic Health in a report on Wednesday, November 7th. Finally, Oppenheimer initiated coverage on shares of Genomic Health in a research report on Wednesday, December 19th. They issued a market perform rating for the company. Nine equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the company. Genomic Health has an average rating of Buy and a consensus price target of $63.13.

NASDAQ GHDX traded down $5.31 during trading hours on Thursday, hitting $78.35. 1,008,519 shares of the company’s stock traded hands, compared to its average volume of 344,894. The firm has a market capitalization of $3.02 billion, a price-to-earnings ratio of 7,835.00 and a beta of 0.88. Genomic Health has a 52 week low of $30.04 and a 52 week high of $92.18.

Genomic Health (NASDAQ:GHDX) last announced its earnings results on Wednesday, February 20th. The medical research company reported $0.32 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.30 by $0.02. The business had revenue of $104.56 million for the quarter, compared to the consensus estimate of $101.55 million. Genomic Health had a net margin of 4.95% and a return on equity of 14.05%. The business’s revenue for the quarter was up 22.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.05 earnings per share. Analysts predict that Genomic Health will post 1.06 EPS for the current fiscal year.

In other news, CEO Kimberly J. Popovits sold 47,900 shares of the business’s stock in a transaction dated Thursday, February 14th. The shares were sold at an average price of $81.70, for a total transaction of $3,913,430.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CFO G Bradley Cole sold 15,000 shares of the business’s stock in a transaction dated Tuesday, February 12th. The shares were sold at an average price of $80.87, for a total transaction of $1,213,050.00. The disclosure for this sale can be found here. Insiders have sold a total of 2,177,707 shares of company stock valued at $161,807,112 over the last three months. 45.80% of the stock is currently owned by insiders.

TRADEMARK VIOLATION WARNING: This piece was originally posted by WKRB News and is owned by of WKRB News. If you are viewing this piece on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece can be accessed at

Genomic Health Company Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Featured Story: Trading Ex-Dividend

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with's FREE daily email newsletter.